Cantor Fitzgerald Forecasts Pharvaris FY2026 Earnings

Pharvaris (NASDAQ:PHVS - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings estimates for Pharvaris in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($3.75) per share for the year. Cantor Fitzgerald has a "Overweight" rating and a $25.00 price target on the stock. The consensus estimate for Pharvaris' current full-year earnings is ($2.71) per share.

A number of other equities research analysts have also recently commented on PHVS. Guggenheim began coverage on shares of Pharvaris in a report on Wednesday. They issued a "buy" rating and a $32.00 price target for the company. Wedbush restated an "outperform" rating and set a $27.00 price objective on shares of Pharvaris in a research note on Thursday, June 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $36.20.

Pharvaris Stock Up 0.3%

Shares of PHVS stock traded up $0.05 during trading hours on Wednesday, reaching $17.10. The company's stock had a trading volume of 3,880 shares, compared to its average volume of 74,953. The firm's 50 day simple moving average is $15.75 and its 200-day simple moving average is $17.00. The company has a market capitalization of $894.16 million, a price-to-earnings ratio of -6.11 and a beta of -2.86. Pharvaris has a fifty-two week low of $11.51 and a fifty-two week high of $25.50.

Pharvaris (NASDAQ:PHVS - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.09).

Hedge Funds Weigh In On Pharvaris

Several hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in shares of Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after buying an additional 2,847 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new position in Pharvaris in the 4th quarter worth approximately $64,000. KLP Kapitalforvaltning AS purchased a new position in shares of Pharvaris in the fourth quarter worth $111,000. Point72 Asset Management L.P. bought a new position in shares of Pharvaris during the fourth quarter worth $152,000. Finally, Legal & General Group Plc increased its holdings in Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock valued at $189,000 after acquiring an additional 994 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.